Vistagen Therapeutics (VTGN) EPS (Weighted Average and Diluted) (2023 - 2025)
Historic EPS (Weighted Average and Diluted) for Vistagen Therapeutics (VTGN) over the last 7 years, with Q4 2025 value amounting to -$0.45.
- Vistagen Therapeutics' EPS (Weighted Average and Diluted) rose 217.39% to -$0.45 in Q4 2025 from the same period last year, while for Dec 2025 it was -$1.9, marking a year-over-year decrease of 2837.84%. This contributed to the annual value of -$1.67 for FY2025, which is 955.6% down from last year.
- As of Q4 2025, Vistagen Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.45, which was up 217.39% from -$0.54 recorded in Q3 2025.
- In the past 5 years, Vistagen Therapeutics' EPS (Weighted Average and Diluted) ranged from a high of -$0.22 in Q4 2023 and a low of -$1.76 during Q1 2023
- In the last 3 years, Vistagen Therapeutics' EPS (Weighted Average and Diluted) had a median value of -$0.46 in 2024 and averaged -$0.58.
- Examining YoY changes over the last 5 years, Vistagen Therapeutics' EPS (Weighted Average and Diluted) showed a top increase of 8577.18% in 2024 and a maximum decrease of 10909.09% in 2024.
- Quarter analysis of 3 years shows Vistagen Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.22 in 2023, then crashed by 109.09% to -$0.46 in 2024, then increased by 2.17% to -$0.45 in 2025.
- Its EPS (Weighted Average and Diluted) stands at -$0.45 for Q4 2025, versus -$0.54 for Q3 2025 and -$0.47 for Q2 2025.